Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2003
08/20/2003CN1118460C Pyrimidine derivatives as 5HT2C-receptor antagonists
08/20/2003CN1118459C Pyrimidinedione, pyrimidi netrione, triazinedione, tetrahydroquinazolinedione derivatives as alpha-adrenergic receptor antagonists
08/20/2003CN1118458C Pyrimidinyl derivatives as interleukin inhibitors
08/20/2003CN1118457C Cyclic diamine compound and medicine containing the same
08/20/2003CN1118454C Heterocyclic derivative and medicine
08/20/2003CN1118452C 1-[(1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, its producing process medicinal composition containing the same compound and intermediate of the compound
08/20/2003CN1118451C Acylated derivatives of melatonin and its analogues as medicine
08/20/2003CN1118450C Novel L-threonic acid derivatives
08/20/2003CN1118308C Device for transfermal electrotransporting fentanyl and sufentanil
08/20/2003CN1118307C Device for transdermal electrotransport delivery of fentanyl and sufentanil
08/20/2003CN1118301C Bioresorbable oxidized cellulose composite material for prevention of postsurgical adhesions
08/20/2003CN1118297C Chinese patent medicine for treating rheumatic hyperosteogeny and its preparing process
08/20/2003CN1118294C Preparation of medicine fo treating stomach diseases
08/20/2003CN1118289C Health product for improving sleep
08/20/2003CN1118286C Oral medicine for treating gastroenteristic diseases and its preparation
08/20/2003CN1118285C Plaster for treating wind-cold arthritis with fixed pain caused by dampness
08/20/2003CN1118284C Medicinal composition for treating beriberi and preparing process thereof
08/20/2003CN1118283C Gastropathy treating medicine and its prepn.
08/20/2003CN1118281C New use of seeweed polyose sulphate
08/20/2003CN1118279C Qunisite of application in medicine preparation for inhibiting pterygium development and postoperative recurrence thereof
08/20/2003CN1118278C Application of ursolic acid in medicine for treating viral hepatitis
08/20/2003CN1118277C Medical aerosol for treating diseases of respiratory system
08/20/2003CN1118250C Composition, cigarette and cigarette filtering tip
08/20/2003CN1118248C Method for producing fat mixture
08/19/2003US6609014 Use of PDT to inhibit intimal hyperplasia
08/19/2003US6608715 Wavelength converter using Bragg-grating
08/19/2003US6608227 Benzylcycloalkyl amines as modulators of chemokine receptor activity
08/19/2003US6608218 Such as 1-(cyclopentyloxy-(3,4-dichloro-phenyl)-acetyl)-3-methyl-urea for treatment of diabetes
08/19/2003US6608203 Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
08/19/2003US6608197 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
08/19/2003US6608196 Structurally diverse; parallel approach
08/19/2003US6608194 Hypolipidemic, antihyperglycemic, antiobesity and hypocholes-terolemic agents
08/19/2003US6608192 Collections of compounds
08/19/2003US6608191 Antisense oligonucleotide of given sequence; capable of inhibiting the function of viral RNA
08/19/2003US6608182 Human vascular endothelial growth factor 2
08/19/2003US6608112 Batimastat BB94 ("Batimastat")
08/19/2003US6608111 Estrogenic carboxylic acids; administering bisdehydrodoisynolic acid
08/19/2003US6608110 Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
08/19/2003US6608109 Replacement for steroids and for stimulating an immune response; in a form which is palatable; acid pH less than 7.0; citric acid
08/19/2003US6608108 Method for treatment of tumors using nordihydroguaiaretic acid derivatives
08/19/2003US6608107 Administering gossypol; kits to treat patients
08/19/2003US6608106 Contacting the cell with an amount of dehydroascorbic acid effective to increase the concentration of ascorbic acid in the cell
08/19/2003US6608105 For therapy and prophylaxis of diseases such as cachexia attributed to cancer or infections, rheumatoid arthritis, inflammatory diseases, osteoarthritis, systemic lupus erythematosus, rejection during bone marrow transplantation
08/19/2003US6608104 Gem substituted hydroxamic acids
08/19/2003US6608103 Inhibitor for neovasculation, cell multiplication, lumen formation and FGF
08/19/2003US6608102 Urinary tract infections caused by P-type Escherichia coli
08/19/2003US6608101 1, 3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
08/19/2003US6608099 Indole sPLA2 inhibitors
08/19/2003US6608097 Materials and methods for the treatment of hypertension and angina
08/19/2003US6608096 Compounds and methods for use thereof in the treatment of cancer or viral infections
08/19/2003US6608095 Sulfonylbenzene and sulfonamidobenzene compounds which inhibit COX-2; treatment of a medical condition in which prostaglandins are implicated as pathogens
08/19/2003US6608094 Breaking preformed AGE
08/19/2003US6608092 Crystals of benzimidazole compounds
08/19/2003US6608091 Increasing solid state percentage by rinsing with a short chain alcohol or tetrahydrofuran and drying; antisecretory agents
08/19/2003US6608089 Derivatives of flavones, xanthones and coumarins
08/19/2003US6608088 Use of donerezil for the treatment of functional and/or organic pain syndromes
08/19/2003US6608087 Gyrase inhibitors and uses thereof
08/19/2003US6608085 Administering for neuroprotection
08/19/2003US6608084 Treatment of human or non-human animal patient suffering from, or subject to, condition which can be ameliorated by administration of inhibitor of alpha 4 beta 1 mediated cell adhesion
08/19/2003US6608083 Treatment and/or prophylaxis of convulsive disorders, renal disorders, urinary incontinence, ocular inflammation, eating disorders, inflammatory pain, allergic rhinitis, psoriasis,neurodegenerative disorders, Huntington's disease,
08/19/2003US6608081 Treating pneumonia
08/19/2003US6608077 Il-8 receptor antagonists
08/19/2003US6608076 Treating topoisomerase I inhibitor-related disease in mammals
08/19/2003US6608075 Preventing opioid induced inhibition of gastrointestinal motility by orally administering an enterically coated quaternary derivative of noroxymorphone, (methylnaltrexone) prior to administering an opioid such as morphine
08/19/2003US6608074 Administering during follicular phase of female menstrual cycle and in luteal phase, a competitive progesterone antagonist, which is less than an ovulation-inhibiting dose and less than an abortion-inductive dose
08/19/2003US6608073 Intranasal codeine for the rapid suppression of cough and rapid relief of pain
08/19/2003US6608072 Inhibiting production of soluble tumor necrosis factor or reducing inflammation
08/19/2003US6608071 Angiogenesis inhibitors as antitumor agents
08/19/2003US6608070 Useful for treatment of medical condition in which prostaglandins are implicated as pathogens
08/19/2003US6608069 Phenyl xanthine derivatives
08/19/2003US6608068 Substituted indoline derivative compounds which are antagonists of the progesterone receptor; contraceptives; antineoplastic agents
08/19/2003US6608067 Inhibitors of serine proteases, particularly HCV NS3 protease
08/19/2003US6608066 Tissue factor antagonists and methods of use thereof
08/19/2003US6608065 Use of cGMP phosphodiesterase inhibitors in methods to treat female sexual dysfunction
08/19/2003US6608064 Pharmaceutical agents for the treatment of Parkinson's disease, ADHD and microadenomas
08/19/2003US6608063 For example: (2-(3-amino-4-nitrophenyl)amino)ethyl)(6-(2,4-dichlorophenyl-5-nitropyrazin -2-yl)-amine; antidiabetic, -carcingenic and ischemic agents; nervous and cardiovascular system disorders; immunotherapy; obesity; syndromes
08/19/2003US6608062 Ligands for gamma-aminobutyric acid receptors; treatment and/or prevention of central nervous system disorders, including anxiety
08/19/2003US6608056 Phosphatidylinositol 3-kinase inhibitors and carcinostatic agents
08/19/2003US6608054 Pharmaceutical compositions based on anticholinergics and endothelin antagonists
08/19/2003US6608053 Phosphatidylinositol 3-kinase (PI3K) inhibitors/anticancer agents such as N-(2-(3-benzenesulfonylaminophenyl)-4-morphoniloquinazolin-6-yl)acetamide
08/19/2003US6608051 Compositions and methods for treating blood
08/19/2003US6608047 Use of low dosage amount of spironolactone for treatment of cardiovascular disease
08/19/2003US6608046 β-lactamase and DD-peptidase inhibitors
08/19/2003US6608044 Inhibition of TNF activity
08/19/2003US6608043 Administering complex of hyaluronic acid and zinc to patient having arthritic disease
08/19/2003US6608042 Decyclization with an alkali metal or quaternary ammonium borohydride; antiinflammatory agents
08/19/2003US6608041 Analgesics combined with naturally-occurring chondroprotective agents
08/19/2003US6608037 TCF responsive element
08/19/2003US6608036 Oligonucleotide N3′→P5′ thiophosphoramidates: their synthesis and administration to treat neoplasms
08/19/2003US6608035 Orally administering to mammal oligonucleotide of 15 to 30 nucleotides, comprising phosphorothioate linkages between nucleosides and 2'-O-alkoxyalkyl-ribonucleotides at each end, whereby oligonucleotide is intact in liver and kidney tissue
08/19/2003US6608034 Immunovectors for the intracellular and intranuclear transport
08/19/2003US6608033 Treatment or prevention of coccidiosis
08/19/2003US6608032 Medicinal compositions
08/19/2003US6608031 Peptide comprising specified amino acid sequence
08/19/2003US6608030 Inhibitor of cathepsin S based upon peptide sequence which comprises at least about 2-20 consecutive residues from preferred invariant chain cleavage site of cathepsin S, spanning from residue 68 to residue 90 of specified sequence
08/19/2003US6607882 Regulation of endogenous gene expression in cells using zinc finger proteins
08/19/2003US6607880 Methods and reagents for modulating apoptosis
08/19/2003US6607784 Microprecipitation method for preparing submicron suspensions
08/19/2003US6607758 Methods for inhibiting and reducing amyloid fibril formation associated with Alzheimer's Disease and other amyloidoses
08/19/2003US6607757 At least 13% glucoside isoflavones and 0.6-1.5 parts 3 soya saponins per 1 part by weight of glucoside isoflavones; treating pre or post menopausal symptoms, breast and prostate cancer, and alcoholism
1 ... 5372 5373 5374 5375 5376 5377 5378 5379 5380 5381 5382 5383 5384 5385 5386 5387 5388 5389 5390 5391 5392 ... 7860